Your browser doesn't support javascript.
loading
The impact of MEIS1 TALE homeodomain transcription factor knockdown on glioma stem cell growth.
Kim, Hyun-Jin; Batara, Don Carlo; Jeon, Young-Jun; Lee, Seongsoo; Beck, Samuel; Kim, Sung-Hak.
Affiliation
  • Kim HJ; Animal Molecular Biochemistry Laboratory, Department of Animal Science, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, Republic of Korea.
  • Batara DC; Animal Molecular Biochemistry Laboratory, Department of Animal Science, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, Republic of Korea.
  • Jeon YJ; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon-si, Gyeonggi-do, Republic of Korea.
  • Lee S; Gwangju Center, Korea Basic Science Institute (KBSI), Gwangju, Republic of Korea.
  • Beck S; Department of Systems Biotechnology, Chung-Ang University, Anseong-si, Gyeonggi-do, Republic of Korea.
  • Kim SH; Department of Dermatology, Center for Aging Research, Chobanian & Avedisian School of Medicine, Boston University, Boston, USA.
Anim Cells Syst (Seoul) ; 28(1): 93-109, 2024.
Article in En | MEDLINE | ID: mdl-38487309
ABSTRACT
Myeloid ecotropic virus insertion site 1 (MEIS1) is a HOX co-factor necessary for organ development and normal hematopoiesis. Recently, MEIS1 has been linked to the development and progression of various cancers. However, its role in gliomagenesis particularly on glioma stem cells (GSCs) remains unclear. Here, we demonstrate that MEIS1 is highly upregulated in GSCs compared to normal, and glioma cells and to its differentiated counterparts. Inhibition of MEIS1 expression by shRNA significantly reduced GSC growth in both in vitro and in vivo experiments. On the other hand, integrated transcriptomics analyses of glioma datasets revealed that MEIS1 expression is correlated to cell cycle-related genes. Clinical data analysis revealed that MEIS1 expression is elevated in high-grade gliomas, and patients with high MEIS1 levels have poorer overall survival outcomes. The findings suggest that MEIS1 is a prognostic biomarker for glioma patients and a possible target for developing novel therapeutic strategies against GBM.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Anim Cells Syst (Seoul) Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Anim Cells Syst (Seoul) Year: 2024 Document type: Article